Abstracts tagged "Juvenile idiopathic arthritis"

Abstract Number: 118 • 2023 Pediatric Rheumatology Symposium
Serum Hepatocyte Growth Factor in Children with Juvenile Idiopathic Arthritis
Natalia Shevchenko and Olga Pavlova, V. N. Karazin Kharkiv National University, Kharkiv, Ukraine
Background/Purpose: Only limited data are available on the risk of liver fibrosis in patients with rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) on long-term…
Abstract Number: 037 • 2023 Pediatric Rheumatology Symposium
Transcriptional Analysis of CD14+ Monocytes During Macrophage Activation Syndrome Highlights Role for Interferons and RNA Sensing in Monocytes
Susan Canny¹, Hannah DeBerg², Griffin Gessay², Ailing Lu³, Mary Eckert¹, Andrea La Bella⁴, Susan Shenoi⁵, Joyce Hui-Yuen⁶, Betsy Barnes⁷ and Jessica Hamerman², ¹Seattle Children's Hospital, Seattle, WA, ²Benaroya Research Institute, Seattle, WA, ³Feinstein Institutes for Medical Research, Manhasset, NY, ⁴Northwell Health, Cohen Children's Medical Center, New Hyde Park, NY, ⁵Seattle Children's Hospital, Seattle, WA, ⁶Cohen Children's Medical Center, Northwell Health, Lake Success, New York; Center for Autoimmune, Musculoskeletal, and Hematopoietic Diseases Research, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, ⁷Center for Autoimmune, Musculoskeletal, and Hematopoietic Diseases Research, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY
Background/Purpose: Macrophage activation syndrome (MAS), a form of secondary hemophagocytic lymphohistiocytosis (HLH), is a potentially fatal complication of rheumatic diseases. MAS is a dysfunctional hyperinflammatory…
Abstract Number: 119 • 2023 Pediatric Rheumatology Symposium
Laser Flare Photometery in the Pediatric Rheumatology Clinic as a Screening Tool for Juvenile Idiopathic Arthritis Associated Uveitis
Kaleo Ede¹, Michael Shishov², Elisa Wershba², Nikita Goswami², Sabrina Gorry², Malin Jospeh², Lucia Mirea² and James O'neil², ¹Phoenix Children's Hosptial; University of Arizona College of Medicine- Phoenix, Phoenix, AZ, ²Phoenix Children's Hospital, Phoenix, AZ
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common chronic rheumatic disease in childhood, affecting 1 to 22 per 100,000 children. JIA-associated uveitis is known…
Abstract Number: L12 • ACR Convergence 2022
First Line Treatment Using Recombinant IL-1Receptor Antagonist in New Onset Systemic Juvenile Idiopathic Arthritis Is an Effective Treatment Strategy, Irrespective of HLA DRB1 Background
Remco Erkens¹, Rashmi Sinha², Alex Pickering³, Grant Schulert⁴, Alexei Grom⁴, Lars van der Veken¹, Hanneke van Deutekom¹, Jorg Calis¹, Jorg van Loosdregt⁵ and Sebastiaan Vastert¹, ¹University Medical Center Utrecht, Utrecht, Netherlands, ²Systemic JIA Foundation, Cincinnati, OH, ³Systemic JIA Foundation, San Francisso, CA, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵University Medical Center Utrecht, Wilhelmina Children's Hospital, Zeist, Netherlands
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) is a severe subtype of JIA. Recently, interstitial lung disease (SJIA-LD) has been reported as a severe complication of…
Abstract Number: 0740 • ACR Convergence 2022
Real-World Demographics, Clinical Characteristics, and Treatment Patterns of Patients Treated with Emapalumab for Secondary Hemophagocytic Lymphohistiocytosis in the United States: The REAL-HLH Study
Carl Allen¹, Shanmuganathan Chandrakasan², Michael Jordan³, Jennifer Leiding⁴, Abiola Oladapo⁵, Priti Pednekar⁶, Kelly Walkovich⁷ and John Yee⁸, ¹Baylor College of Medicine, Houston, TX, ²Emory University School of Medicine, Atlanta, GA, ³University of Cincinnati, Cincinnati, OH, ⁴Johns Hopkins University, Baltimore, MD, ⁵Swedish Orphan Biovitrum AB, Boston, MA, ⁶PRECISIONheor, Los Angeles, CA, ⁷University of Michigan Health, Ann Arbor, MI, ⁸Sobi - North America, Waltham, MA
Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening, hyperinflammatory syndrome caused by overproduction of proinflammatory cytokines, e.g., interferon gamma (IFNγ). Secondary HLH (sHLH), a subtype…
Abstract Number: 0868 • ACR Convergence 2022
Spondyloarthritis and Neonatal Factors Affecting the Gut Microbiome
Joy Um¹, Douglas Einstadter², Myung-Yong Um³ and Maria Antonelli¹, ¹Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, ²Center for Health Care Research and Policy, Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, ³Department of Social Welfare, Sungkyunkwan University, Seoul, Republic of Korea
Background/Purpose: Spondyloarthritis (SpA) consists of clinically and genetically related but phenotypically distinct disorders, including ankylosing spondylitis, enteropathic arthritis, psoriatic arthritis, reactive arthritis, and enthesitis-related arthritis…
Abstract Number: 1939 • ACR Convergence 2022
Safety and Humoral Response Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-onset Autoimmune Inflammatory Rheumatic Diseases
Merav Heshin-Bekenstein¹, amit ziv², NATASA TOPLAK³, Adi Miller Barmak⁴, Siman Lazauskas⁵, Danielle Kadishevich⁶, Efrat Ben Nun⁶, Esther Saiag⁷, Yonatan Butbul Aviel⁴, Gabi Shefer⁷, Sara Pel⁸, Ori Elkayam⁷ and Yosef Uziel⁹, ¹Dana Dwek Children's Hospital, Tel Aviv Medical Center Israel, Binyamina, Israel, ²Meir Hospital, Kfar Saba, Israel, ³University of Ljubljana, Ljubljana, Slovenia, ⁴Rambam Medical Center, Haifa, Israel, ⁵Tel Aviv Medical Center, Tel Aviv, Israel, ⁶Meir Medical Center, Kfar Saba, Israel, ⁷Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁸Department of Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel, ⁹Meir Medical Center, Kfar Saba; Sackler School of Medicine, Tel Aviv University, Kfar Saba, Israel
Background/Purpose: Long-term data on the safety and dynamics of the immune response to the BNT162b2 mRNA COVID-19 vaccine in adolescents with juvenile-onset autoimmune inflammatory rheumatic…
Abstract Number: 0808 • ACR Convergence 2022
Transitional Care in Juvenile Idiopathic Arthritis: Timing, Prevalence of Subtypes and Treatment Profile in a Spanish Tertiary Hospital
Cristobal Pavez Perales¹, Alba Torrat Novés², José Ivorra Cortés¹, Samuel Leal Rodriguez¹, Anderson V Huaylla Quispe³, Carmen Riesco Bárcena², Laura Mas Sanchez¹, Pablo Muñoz Martinez⁴, Elena Grau García¹, Elvira Vicens Bernabeu¹, José Eloy Oller Rodrígez¹, Francisco Miguel Ortiz Sanjuan⁵, Isabel Martínez-Cordellat¹, Rosa Negueroles Albuixech¹, Berta Lopez Montecinos⁶, Carmen Nájera Herranz¹, Inés Cánovas Olmos¹, Daniel Ramos Castro¹, Inmaculada Calvo Penades⁷, Luis González Puig⁸ and José andrés Román ivorra⁹, ¹Rheumatology Department. Hospital Universitario y Politécnico La Fe, València, Spain, ²Rheumatology Department. Hospital Universitario y Politécnico La Fe, València, ³Rheumatology Department. Hospital Universitario y Politécnico La Fe, València, Comunidad Valenciana, Spain, ⁴Rheumatology Department. Hospital Universitario y Politécnico La Fe, Sagunto, Spain, ⁵Rheumatology Department. Hospital Universitario y Politécnico La Fe, Spain, Spain, ⁶Pediatric Rheumatology Unit. Hospital Universitario y Politécnico La Fe, València, Comunidad Valenciana, Spain, ⁷Pediatric Rheumatology Unit, Hospital Universitario y Politécnico La Fe, València, Spain, ⁸Rheumatology Department. Hospital Universitario y Politécnico La Fe, Torrente, Valencia, Spain, ⁹Hospital Universitari i Politécnic la Fe, València, Spain
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the leading cause of chronic inflammatory rheumatic disease in children. It's classified into subtypes with different relative prevalences depending…
Abstract Number: 0870 • ACR Convergence 2022
Knee Acoustic Emissions as a Noninvasive Biomarker of Articular Health in Juvenile Idiopathic Arthritis
Sevda Gharehbaghi¹, Emily Moise¹, Priya Brito², Lori Ponder³, Omer Inan¹ and Sampath Prahalad⁴, ¹Georgia Institute of Technology, Atlanta, GA, ²Emory University, Atlanta, GA, ³Children's Healthcare of Atlanta, Atlanta, GA, ⁴Emory + Children's Pediatric Institute, Atlanta, GA
Background/Purpose: Juvenile idiopathic arthritis (JIA) refers to all forms of autoimmune arthritis in children with undetermined etiology, and thus it is the most prevalent chronic…
Abstract Number: 1943 • ACR Convergence 2022
Prevalence and Evolution of Undifferentiated Periodic Fever Syndromes in an Academic Pediatric Rheumatology Practice
Jacob Anderson¹, Catherine Bingham², Lisabeth Scalzi³, Natalya Gaffney⁴, Kimberly Hays⁵, Brandt Groh² and Timothy Hahn², ¹Phoenix Children's Hospital, Phoenix, AZ, ²Penn State Children's Hospital, Hershey, PA, ³Penn State Health, Hummelstown, PA, ⁴Self-Employed, Carlisle, PA, ⁵Penn State Health, Hershey, PA
Background/Purpose: Periodic Fever Syndromes (PFS) are common referrals to pediatric rheumatology clinics. While the syndrome of Periodic Fevers, Aphthous stomatitis, Pharyngitis, and Adenitis (PFAPA) is…
Abstract Number: 0850 • ACR Convergence 2022
Outcomes of Patients with Juvenile Idiopathic Arthritis Following Failure of Initial Tumor Necrosis Factor Inhibitor Medication in the Childhood Arthritis and Rheumatology Research Alliance Registry
Melissa Mannion¹, Shahla Amin², Stephen Balevic³, Colleen Correll⁴, Timothy Beukelman¹ and , for the CARRA Registry Investigators⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²Childhood Arthritis and Rheumatology Research Alliance, Washington, DC, ³Duke University, Durham, NC, ⁴University of Minnesota, Minneapolis, MN, ⁵CARRA, Washington, DC
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are the most commonly used first biologics to treat juvenile idiopathic arthritis (JIA), but it is unknown what subsequent…
Abstract Number: 0873 • ACR Convergence 2022
Celiac-Associated Arthritis: Clinical Features, Treatment, and Outcomes
Ana Luiza Altaffer¹ and Pamela Weiss², ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Glen Mills, PA
Background/Purpose: Although arthritis is recognized as one of the extra-intestinal manifestations of celiac disease, little is known about the clinical course and outcomes of celiac-associated…
Abstract Number: 1944 • ACR Convergence 2022
Description and Delays in Care in the Bridge to Adult Care from Childhood for Young Adults with Rheumatic Disease (BACC YARD) Program, a Pediatric-to-Adult Rheumatology Transition Program
John Bridges¹, Livie Huie², Amanda Alexander³, Randy Cron², Maria Danila², Victoria Gennaro⁴, Laura Hughes², Bailey Lipham⁵, Linda McAllister⁶, Matthew Mullen⁷, Annelle Reed⁴, Daniel Reiff², Carolyn Smith⁴, Emily Smitherman², Matthew Stoll², Peter Weiser² and Melissa Mannion², ¹University of Alabama at Birmingham/Children's of Alabama, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Homewood, AL, ⁴Children's of Alabama, Birmingham, AL, ⁵University of Alabama Medical School, Birmingham, AL, ⁶Children's of Alabama, Trussville, AL, ⁷University of Alabama-Birmingham, Vestavia Hills, AL
Background/Purpose: Children with chronic rheumatic conditions age and require transfer to adult rheumatologists for continued care. The transition period from pediatric to adult-oriented care is…
Abstract Number: 0851 • ACR Convergence 2022
Responsiveness of Patient-Reported Physical Function Measures in Juvenile Arthritis
Alysha Taxter¹, Laura Schanberg², Marc Natter³ and for the CARRA Registry investigators⁴, ¹Nationwide Children's Hospital, Columbus, OH, ²Duke University Medical Center, Durham, NC, ³Boston Children's Hospital, Boston, MA, ⁴CARRA, Washington, DC
Background/Purpose: The ACR Pediatric Criteria (ACR Pedi) contains a core set of outcome variables, including a measure of functional ability, to evaluate improvement over time…
Abstract Number: 0874 • ACR Convergence 2022
A Tale of Many Canadas: Associations of Ethnicity with Juvenile Idiopathic Arthritis Categories and Disease Severity at Presentation in a Multicultural Universal Healthcare Setting: Results from ReACCh-Out
Stephanie Wong¹, Lori Tucker², Kristin Houghton³, David Cabral⁴, Mercedes Chan², Ross Petty³, Andrea Human², Kimberly Morishita³, Rae Yeung⁵, Kiem Oen⁶, Ciaran Duffy⁷, Roberta Berard⁸, Gaelle Chedeville⁹, Thomas Loughin¹⁰, Matthew Berkowitz¹⁰ and Jaime Guzman¹¹, ¹University of British Columbia, Vancouver, BC, Canada, ²British Columbia Children's Hospital, Vancouver, BC, Canada, ³University of British Columbia - Vancouver, Vancouver, BC, Canada, ⁴BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ⁵The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁶University of Manitoba, Toronto, ON, Canada, ⁷University of Ottawa, Ottawa, ON, Canada, ⁸London Health Sciences Centre, London, ON, Canada, ⁹McGill University, Montréal, QC, Canada, ¹⁰Simon Fraser University, Vancouver, BC, Canada, ¹¹University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: The distribution of Juvenile Idiopathic Arthritis (JIA) categories and disease severity at presentation vary across countries, however it is unclear how much of this…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].